| Literature DB >> 34274535 |
Bingchen Han1, Felix Alonso-Valenteen2, Zhe Wang3, Nan Deng4, Tian-Yu Lee5, Bowen Gao5, Ying Zhang3, Yali Xu6, Xinfeng Zhang5, Sandrine Billet7, Xuemo Fan8, Stephen Shiao9, Neil Bhowmick7, Lali Medina-Kauwe2, Armando Giuliano5, Xiaojiang Cui10.
Abstract
Triple-negative breast cancer (TNBC) has a high propensity for organ-specific metastasis. However, the underlying mechanisms are not well understood. Here we show that the primary TNBC tumor-derived C-X-C motif chemokines 1/2/8 (CXCL1/2/8) stimulate lung-resident fibroblasts to produce the C-C motif chemokines 2/7 (CCL2/7), which, in turn, activate cholesterol synthesis in lung-colonizing TNBC cells and induce angiogenesis at lung metastatic sites. Inhibiting cholesterol synthesis in lung-colonizing breast tumor cells by pulmonary administration of simvastatin-carrying HER3-targeting nanoparticles reduces angiogenesis and growth of lung metastases in a syngeneic TNBC mouse model. Our findings reveal a novel, chemokine-regulated mechanism for the cholesterol synthesis pathway and a critical role of metastatic site-specific cholesterol synthesis in the pulmonary tropism of TNBC metastasis. The study has implications for the unresolved epidemiological observation that use of cholesterol-lowering drugs has no effect on breast cancer incidence but can unexpectedly reduce breast cancer mortality, suggesting interventions of cholesterol synthesis in lung metastases as an effective treatment to improve survival in individuals with TNBC.Entities:
Keywords: FOXC1; chemokine; cholesterol; lung fibroblasts; lung metastasis; triple-negative breast cancer
Mesh:
Substances:
Year: 2021 PMID: 34274535 PMCID: PMC8821896 DOI: 10.1016/j.ymthe.2021.07.003
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454